Pyc.asx

Financial Times Close. Search the FT Search. Show more World link World. Pyc.asx more US link US.

Driven to transform the lives of patients through a new generation of RNA therapeutics. PYC Therapeutics combines world-leading RNA therapeutic drug design with a revolutionary delivery technology based on a proprietary library of naturally derived Cell Penetrating Peptides CPPs to solve the delivery challenge associated with traditional RNA therapeutics. PYC has a initial focus on ophthalmology, neurodevelopmental and kidney diseases and aims to apply its platform technology to further indications. Our Platform is highly versatile and modular, offering broad potential across therapeutic areas. PYC's goal is to provide patients with no current treatment options a therapeutic that addresses the underlying cause of the disease. Truly Life-Changing Science.

Pyc.asx

PYC Therapeutics Limited. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. About the company. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. Revenue is forecast to grow Shareholders have been diluted in the past year. Significant insider selling over the past 3 months. Currently unprofitable and not forecast to become profitable over the next 3 years. Mar New major risk - Financial position Nov

Pyc.asx refer to our Financial Services Guide for more information. FREE membership. Media centre.

Looks you are already a member. Please enter your password to proceed. Forgotten password? Click here. Please make sure your payment details are up to date to continue your membership. Please contact Member Services on support investsmart.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Pyc.asx

PYC Therapeutics Limited. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. About the company. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. Revenue is forecast to grow Shareholders have been diluted in the past year.

Crimeisdown

See more updates Recent updates. Start Free Trial. Search the FT Search. Market data is provided and copyrighted by Thomson Reuters and Morningstar. Not a member? Is PYC overvalued? Please make sure your payment details are up to date to continue your membership. Real Brand Holdings Limited. Email is required. Password is required. Use our equities screener to discover other potential opportunities. Health Care Pharmaceuticals and Biotechnology. Schedule a call. Confirm password. Price AUD 0.

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company, which offers ribonucleic acid RNA therapeutics in patients with unmeet genetic diseases.

Registration for this event is available only to Intelligent Investor members. Intelligent Investor Membership. Actions Add to watchlist Add to portfolio Add an alert. Trade our derivatives market. See Fair Value and valuation analysis. FREE membership. Sundance Energy Australia Limited. Investment options. Currently unprofitable and not forecast to become profitable over the next 3 years. Market data is provided and copyrighted by Thomson Reuters and Morningstar. Still having trouble viewing content? Schedule a call. Please wait.